Publications

Detailed Information

SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease

Cited 22 time in Web of Science Cited 23 time in Scopus
Authors

Moon, Jun Sung; Hong, Jun Hwa; Jung, Yong Jin; Ferrannini, Ele; Nauck, Michael A.; Lim, Soo

Issue Date
2022-06
Publisher
Elsevier BV
Citation
Trends in Endocrinology and Metabolism, Vol.33 No.6, pp.424-442
Abstract
© 2022 Elsevier LtdMetabolic dysfunction-associated fatty liver disease (MAFLD) is a chronic condition that affects nearly one billion people globally, characterized by triacylglycerol accumulation in the liver as a consequence of metabolic abnormalities (obesity and impaired glucose regulation). Low-grade inflammation, oxidative stress, mitochondrial dysfunction, and dysbiosis in gut microbiota are involved in the etiology of MAFLD, and both cardiovascular events and hepatic complications are the long-term consequences. In the absence of approved therapies for this condition, sodium–glucose cotransporter 2 inhibitors (SGLT-2 Is) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have the specific advantage of lowering body weight and providing cardiovascular benefits. Here, we discuss potential roles for SGLT-2 Is and GLP-1 RAs in the prevention and treatment of intrahepatic triacylglycerol accumulation and associated inflammation and/or fibrosis.
ISSN
1043-2760
URI
https://hdl.handle.net/10371/184649
DOI
https://doi.org/10.1016/j.tem.2022.03.005
Files in This Item:
There are no files associated with this item.
Appears in Collections:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share